Barclays
FLNA

Barclays’s Filana Therapeutics FLNA Stock Holding History

Barclays’s Portfolio FLNA Stock Details FLNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-20,000
Closed -$47.2K – 5519
2024
Q4 		$47.2K Hold
20,000
– – ﹤0.01% 4776
2024
Q3 		$589K Buy
+20,000
New +$461K ﹤0.01% 3681
2023
Q4 		– Sell
-141,800
Closed -$2.36M – 5333
2023
Q3 		$2.36M Buy
+141,800
New +$2.81M ﹤0.01% 1785

Other funds holding FLNA

Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
GC
GMT Capital Atlanta, Georgia $1.92B AUM 70.51% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Squarepoint
Squarepoint New York $90.5B AUM 33.95% 1-Year Est. Return

Barclays's FLNA Position: Q2 2026 in Review

Barclays reduced its Filana Therapeutics (FLNA) stake by 99% in Q2 2026, selling an estimated $60K and leaving 292 shares worth $347. The position accounts for ﹤0.01% of the portfolio, ranked #5052.

Barclays first reported a position in FLNA in Q2 2013 and has held it in 27 quarters since. The position peaked at $4.85M in Q4 2021. 84 funds tracked by Wall St. Rank hold FLNA as of Q2 2026.

  • Barclays held 292 shares of Filana Therapeutics worth $347 as of Q2 2026.
  • Barclays sold 42,087 Filana Therapeutics shares in Q2 2026, an estimated $60K.
  • Filana Therapeutics made up ﹤0.01% of Barclays's portfolio in Q2 2026, its #5052 holding.
  • Barclays first reported a position in Filana Therapeutics in Q2 2013 and has held it in 27 quarters since.
  • Barclays's Filana Therapeutics position peaked at $4.85M in Q4 2021.
  • 84 funds tracked by Wall St. Rank held Filana Therapeutics as of Q2 2026.

Based on Barclays's 13F filing for Q2 2026, filed 14 Aug 2026.